Cargando…
Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
Clinical isolates of drug-resistant (isoniazid and/or rifampicin-resistant) Mycobacterium tuberculosis were obtained from 254 patients diagnosed with drug-resistant tuberculosis in Japan from April 2015 to March 2017 in National Hospital Organization hospitals. The 254 patients were approximately 32...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386464/ https://www.ncbi.nlm.nih.gov/pubmed/34232083 http://dx.doi.org/10.1128/mSphere.00978-20 |
_version_ | 1783742268156411904 |
---|---|
author | Mizukoshi, Fuminori Kobayashi, Nobuyuki Kirikae, Fumiko Ohta, Ken Tsuyuguchi, Kazunari Yamada, Noritaka Inoue, Yoshikazu Horiba, Masahide Kawata, Noriko Ichinose, Akiko Miyoshi-Akiyama, Tohru Kiritani, Reiko Funatogawa, Keiji Kirikae, Teruo |
author_facet | Mizukoshi, Fuminori Kobayashi, Nobuyuki Kirikae, Fumiko Ohta, Ken Tsuyuguchi, Kazunari Yamada, Noritaka Inoue, Yoshikazu Horiba, Masahide Kawata, Noriko Ichinose, Akiko Miyoshi-Akiyama, Tohru Kiritani, Reiko Funatogawa, Keiji Kirikae, Teruo |
author_sort | Mizukoshi, Fuminori |
collection | PubMed |
description | Clinical isolates of drug-resistant (isoniazid and/or rifampicin-resistant) Mycobacterium tuberculosis were obtained from 254 patients diagnosed with drug-resistant tuberculosis in Japan from April 2015 to March 2017 in National Hospital Organization hospitals. The 254 patients were approximately 32% of all 795 patients who were diagnosed with culture-confirmed drug-resistant tuberculosis from 2015 to 2016 nationwide in Japan. The whole-genome sequences of all the isolates from the 254 patients and the lineages of these isolates were determined, and phylogenetic trees were constructed based on single nucleotide polymorphism concatemers. Of these patients, 202 (79.5%) were born in Japan and 52 (20.5%) were born elsewhere. Of the 254 drug-resistant isolates, 54 (21.3%) were multidrug resistant, being resistant to both isoniazid and rifampicin. The percentages of multidrug-resistant isolates were significantly higher in foreign-born (38.5% [20/52]) than Japanese-born patients (16.8% [34/202]). Of the 54 multidrug-resistant isolates, nine were extensively drug resistant, which were all obtained from Japanese-born patients. Five extensively drug-resistant isolates were obtained from patients with incipient tuberculosis. A significant number of multidrug-resistant M. tuberculosis strains were isolated from foreign-born patients from Asian countries that have a high tuberculosis burden. Foreign-derived isolates affect the nationwide genetic diversity of drug-resistant M. tuberculosis in Japan. Extensively drug-resistant M. tuberculosis isolates were transmitted among the Japanese population. IMPORTANCE The incidence rate of tuberculosis (TB) in Japan was 11.5 per 100,000 of the population in 2019. Of TB patients in Japan, 61.1% were aged >70 years, and 10.7% were born outside Japan, mostly in Asian countries with a high burden of tuberculosis. Of the tuberculosis patients in the present study, 5.4% and 1.0% showed resistance to isoniazid and rifampicin, respectively, and 0.7% were multidrug resistant. The objective of this study was to clarify the molecular epidemiological properties of drug-resistant tuberculosis in Japan. Molecular epidemiology provides several clues to inform potential measures to control drug-resistant tuberculosis in Japan. |
format | Online Article Text |
id | pubmed-8386464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-83864642021-09-09 Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan Mizukoshi, Fuminori Kobayashi, Nobuyuki Kirikae, Fumiko Ohta, Ken Tsuyuguchi, Kazunari Yamada, Noritaka Inoue, Yoshikazu Horiba, Masahide Kawata, Noriko Ichinose, Akiko Miyoshi-Akiyama, Tohru Kiritani, Reiko Funatogawa, Keiji Kirikae, Teruo mSphere Research Article Clinical isolates of drug-resistant (isoniazid and/or rifampicin-resistant) Mycobacterium tuberculosis were obtained from 254 patients diagnosed with drug-resistant tuberculosis in Japan from April 2015 to March 2017 in National Hospital Organization hospitals. The 254 patients were approximately 32% of all 795 patients who were diagnosed with culture-confirmed drug-resistant tuberculosis from 2015 to 2016 nationwide in Japan. The whole-genome sequences of all the isolates from the 254 patients and the lineages of these isolates were determined, and phylogenetic trees were constructed based on single nucleotide polymorphism concatemers. Of these patients, 202 (79.5%) were born in Japan and 52 (20.5%) were born elsewhere. Of the 254 drug-resistant isolates, 54 (21.3%) were multidrug resistant, being resistant to both isoniazid and rifampicin. The percentages of multidrug-resistant isolates were significantly higher in foreign-born (38.5% [20/52]) than Japanese-born patients (16.8% [34/202]). Of the 54 multidrug-resistant isolates, nine were extensively drug resistant, which were all obtained from Japanese-born patients. Five extensively drug-resistant isolates were obtained from patients with incipient tuberculosis. A significant number of multidrug-resistant M. tuberculosis strains were isolated from foreign-born patients from Asian countries that have a high tuberculosis burden. Foreign-derived isolates affect the nationwide genetic diversity of drug-resistant M. tuberculosis in Japan. Extensively drug-resistant M. tuberculosis isolates were transmitted among the Japanese population. IMPORTANCE The incidence rate of tuberculosis (TB) in Japan was 11.5 per 100,000 of the population in 2019. Of TB patients in Japan, 61.1% were aged >70 years, and 10.7% were born outside Japan, mostly in Asian countries with a high burden of tuberculosis. Of the tuberculosis patients in the present study, 5.4% and 1.0% showed resistance to isoniazid and rifampicin, respectively, and 0.7% were multidrug resistant. The objective of this study was to clarify the molecular epidemiological properties of drug-resistant tuberculosis in Japan. Molecular epidemiology provides several clues to inform potential measures to control drug-resistant tuberculosis in Japan. American Society for Microbiology 2021-07-07 /pmc/articles/PMC8386464/ /pubmed/34232083 http://dx.doi.org/10.1128/mSphere.00978-20 Text en Copyright © 2021 Mizukoshi et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Mizukoshi, Fuminori Kobayashi, Nobuyuki Kirikae, Fumiko Ohta, Ken Tsuyuguchi, Kazunari Yamada, Noritaka Inoue, Yoshikazu Horiba, Masahide Kawata, Noriko Ichinose, Akiko Miyoshi-Akiyama, Tohru Kiritani, Reiko Funatogawa, Keiji Kirikae, Teruo Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan |
title | Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan |
title_full | Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan |
title_fullStr | Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan |
title_full_unstemmed | Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan |
title_short | Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan |
title_sort | molecular epidemiology of drug-resistant mycobacterium tuberculosis in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386464/ https://www.ncbi.nlm.nih.gov/pubmed/34232083 http://dx.doi.org/10.1128/mSphere.00978-20 |
work_keys_str_mv | AT mizukoshifuminori molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT kobayashinobuyuki molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT kirikaefumiko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT ohtaken molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT tsuyuguchikazunari molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT yamadanoritaka molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT inoueyoshikazu molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT horibamasahide molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT kawatanoriko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT ichinoseakiko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT miyoshiakiyamatohru molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT kiritanireiko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT funatogawakeiji molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan AT kirikaeteruo molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan |